Commission pertaining to the licensing of ocean freight forwarders, effective on the corresponding revocation dates shown below:

License Number: 4096.

Name: American Cargo Forwarding, Inc.

Address: 11020 King Street, Suite 350, Overland Park, KS 66210.

Date Revoked: February 21, 1997.

Reason: Failed to maintain a valid surety bond.

License Number: 3109.

Name: Denise Zappola d/b/a Corporate Relocation Services.

Address: 284 McClean Avenue, Staten Island, NY 10305.

Date Revoked: August 29, 1996.

Reason: Surrendered license voluntarily.

Bryant L. VanBrakle,

Director, Bureau of Tariffs, Certification and Licensing.

[FR Doc. 97–7103 Filed 3–19–97; 8:45 am]

BILLING CODE 6730–01–M

Ocean Freight Forwarder License; Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission applications for licenses as ocean freight forwarders pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. app. 1718 and 46 CFR 510).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to contact the Office of Freight Forwarders, Federal Maritime Commission, Washington, DC 20573.

Bottom Line Forwarders, Corp., 10302 N.W. South River Dr., Bay #19, Medley, FL 33178, Officers: Waldy Castro, President, Tensie Barry, Corporate Secretary

Inter World Customs Broker, Inc., Marketing Bldg. (Lobby), J.F. Kennedy Ave. Km 2.5, Puerto Nuevo, PR 00922, Officer: Lawrence Colon Castro, President

Dated: March 17, 1997.

Joseph C. Polking,

Secretary.

[FR Doc. 97–6998 Filed 3–19–97; 8:45 am]

BILLING CODE 6730–01–M

Ocean Freight Forwarder License; Applicants

Notice is hereby given that the following applicants have flied with the Federal Maritime Commission applications for licenses as ocean freight forwarders pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. app. 1718 and 46 CFR 510).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to contact the Office of Freight Forwarders, Federal Maritime Commission, Washington, D.C. 20573.

International Service, Inc., 12000 Beacom Road, Sunbury, OH 43074, Officers: Daniel G. Chase, President, Chris Bartholomew, Stockholder

Trico American Air Freight and Forwarding Co. Inc., 13734 Shoreline Court East, Earth City, MO 63045, Officers: Richard L. Goode, President, Lester E. Maull, Secretary

Impel America packing and Appliances Corp., 5461 N.W. 72nd Avenue, Miami, FL 33166, Officers: Hector V. Marulanda, President, Maria L. Marulanda, Secretary

Dated: March 17, 1997.

Joseph C. Polking,

Secretary.

[FR Doc. 97–7104 Filed 3–19–97; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 14, 1997.

A. Federal Reserve Bank of Cleveland (R. Chris Moore, Senior Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. First Financial Bancorp, Hamilton, Ohio; to merge with Southeastern Indiana Bancorp, Vevay, Indiana, and thereby indirectly acquire Vevay Deposit Bank, Vevay, Indiana.

B. Federal Reserve Bank of Atlanta (Lois Berthaume, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303-2713:

1. Regions Financial Corporation, Birmingham, Alabama; to acquire 100 percent of the voting shares of First Mercantile National Bank, Longwood, Florida.

C. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. CH and JD Byrum, LLC, Indianapolis, Indiana; to become a bank holding company by acquiring 52.4 percent of the voting shares of American State Bank, Lawrenceburg, Indiana, and thereby indirectly acquire American State Corporation, Lawrenceburg, Indiana.

D. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480-2171:

1. Hiawatha Bancshares, Inc., Hager City, Wisconsin; to merge with Glenwood Bancshares, Inc., Glenwood City, Wisconsin, and thereby indirectly acquire First National Bank of Glenwood City, Glenwood City, Wisconsin.

Board of Governors of the Federal Reserve System, March 14, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–6988 Filed 3-19-97; 8:45 am]

BILLING CODE 6210-01-F

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Committee on Employee Benefits of the Federal Reserve System.[1]

TIME AND DATE: 2:30 p.m., Tuesday, March 25, 1997.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 2lst Streets, N.W., Washington, D.C. 20551.

[1] The Committee on Employee Benefits considers matters relating to the Retirement, Thrift, Long-Term Disability Income, and Insurance Plans for Employees of the Federal Reserve System.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Proposals relating to Federal Reserve System benefits.
2. Proposed minutes of the Committee on Employee Benefits meetings.
3. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204.

Dated: March 18, 1997.

William W. Wiles,

Secretary of the Board.

[FR Doc. 97–7189 Filed 3–18–97; 11:35 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Universal Newborn Hearing Ad Hoc Group; Teleconference Meetings

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following meetings.

Name: Teleconference meetings of the Ad Hoc Group for Universal Newborn Hearing Screening (UNHS).

Times and Dates: 2 p.m.–3 p.m., April 1, 1997; 2 p.m.–3 p.m., May 6, 1997; 2 p.m.–3 p.m., June 3, 1997; 2 p.m.–3 p.m., July 1, 1997; 2 p.m.–3 p.m., August 5, 1997; 2 p.m.–3 p.m., September 2, 1997.

Place: National Center for Environmental Health, Division of Birth Defects and Developmental Disabilities (DBDDD), Room 2103A, Building 101, 4770 Buford Highway, NE, Atlanta, Georgia 30341. Telephone 770/488–7400.

Status: Open for participation by anyone with an interest in UNHS. All participants in the monthly conference calls are, by definition, members of the Ad Hoc Group for Universal Newborn Hearing Screening. Persons wishing to participate must E-mail or fax their request 1 week prior to the scheduled teleconference date. The e-mail address is unhs@cdc.gov; the fax number is 770/488–7361. Participants will be notified of the toll-free teleconference phone number and a caller code. Each participant will have the responsibility to call in to connect to the conference call. The conference bridge number is limited to 238 callers.

Purpose: This meeting will provide a forum for persons associated with UNHS programs to report and review relevant activities. Each conference call will be comprised of a series of scheduled presentations. Each presentation will be followed by a brief question and answer period. The agenda for the conference call will be determined by the Division of Birth Defects and Developmental Disabilities in collaboration with the Office of Disability and Health, NCEH, (pending approval); in consultation with the National Institute on Deafness and Communicative Disorders, National Institutes of Health; the Bureau of Maternal and Child Health, Health Resources and Services Administration; Office of Special Education and Rehabilitative Services, Department of Education; and others interested in newborn hearing screening.

Suggestions and feedback are invited by conference call planners. Participants requesting to be on the agenda or wishing to make written comments can send their requests or comments to the E-mail address or fax number noted above.

Matters Discussed: Topics to be discussed during the meetings include progress on State and National activities to implement UNHS; progress on establishing State and National data systems on UNHS; and guidelines for establishing screening, diagnosis, and intervention protocols.

For further information contact: June Holstrum, DBDDD, NCEH, CDC, 4770 Buford Highway, NE, M/S F–15, Atlanta, Georgia 30341, telephone 770/488–7401, fax 770/488–7361.

Dated: March 14, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–7016 Filed 3–19–97; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 96E–0442]

Determination of Regulatory Review Period for Purposes of Patent Extension; CEREBYX®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for CEREBYX® and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1382.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product CEREBYX® (fosphenytoin sodium). CEREBYX® is indicated for short-term parenteral administration when other means of phenytoin administration are unavailable, inappropriate, or deemed less advantageous. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for CEREBYX® (U.S. Patent No. 4,260,769) from Warner-Lambert Co. and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated January 21, 1997, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of CEREBYX® represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for